Edison Research raises valuation to €134.0m base on approval of PRIMAvera studyAntoine Balavoine2020-11-25T19:03:34+01:00November 25th, 2020|
Shareholder structure of Pixium Vision following the capital increase with pre-emptive subscription rights of €7.3 millionAntoine Balavoine2020-11-24T13:41:40+01:00November 24th, 2020|
Pixium Vision receives French regulatory authority (ANSM) approval to initiate European PRIMAvera pivotal study of Prima SystemAntoine Balavoine2020-11-20T05:14:22+01:00November 20th, 2020|
Pixium Vision announces its cash position at 30 September 2020admin2020-10-22T19:06:39+02:00October 22nd, 2020|
Pixium Vision Hosting Key Opinion Leader Webinar on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD)admin2020-10-16T12:37:53+02:00October 16th, 2020|
Pixium Vision announces its financial results as of June 30 2020 and provides business updateadmin2020-07-24T15:18:14+02:00July 23rd, 2020|
Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal studyadmin2020-07-06T10:42:42+02:00July 6th, 2020|
Pixium Vision selected to participate in the Next French Healthcare Program organized by Business France and Bpifrance, bolstering presence in the USadmin2020-06-19T12:15:53+02:00June 19th, 2020|
Pixium Vision launches a capital increase with pre-emptive subscription rights for a maximum of €7,8 million for its Prima System pivotal studyadmin2020-06-15T12:26:08+02:00June 12th, 2020|
Pixium Vision announces resumption of Prima System feasibility study in Franceadmin2020-06-08T17:48:15+02:00June 8th, 2020|
Pixium Vision notified on threshold crossing following passive dilutionadmin2020-06-03T20:56:51+02:00June 3rd, 2020|
